FindTrial
Sign In

Study and clinical significance of biomarkers of breast phyllodes tumor

Study and clinical significance of biomarkers of breast phyllodes tumor

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038583
Enrollment
Unknown
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast phyllodes tumor

Interventions

Gold Standard:Phyllode tumour is a group of fibroepithelial neoplasm characterized by a double-layered epithelial component arranged in clefts surrounded by a hypercelluar stromal/mesenchymal componen
Index test:High-throughput&#32
gene&#32
sequencing,gene&#32
mutation&#32
detection,immunohistochemical&#32
detection

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Surgical specimens of phyllodes tumor, fibroadenoma, metaplastic carcinoma and other spindle cell lesions of breast

Exclusion criteria

Exclusion criteria: Surgical specimens other than the above lesions

Design outcomes

Primary

MeasureTime frame
High-throughput gene sequencing;gene mutation;Immunohistochemstry detection;—

Countries

China

Contacts

Public ContactWeiqing Xu

Shanghai General Hospital

xuweiqing152@sina.com+86 13661888020

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026